Pfizer Inc yesterday announced positive top-line results from a phase-III study describing the safety and immunogenicity of Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in the US 65 years of age or older when administered at the same time as the Pfizer-BioNTech COVID-19 vaccine or when each vaccine was given with placebo, a company statement informed.
The statement also said that responses elicited by Prevnar 20 for all 20 serotypes were similar whether given with a dose of the Pfizer-BioNTech COVID-19 vaccine (n=190) or with placebo (n=191). Responses to a booster dose of the Pfizer-BioNTech COVID-19 vaccine were also similar when given with Prevnar 20 or given with placebo (n=189).
The initiation of the study exploring the coadministration of Prevnar 20 along with a booster dose of the Pfizer-BioNTech COVID-19 vaccine in older adults was announced in May 2021. The study recruited adults from the pivotal phase-III Pfizer-BioNTech COVID-19 vaccine clinical trial and included adults who received their second dose of the vaccine at least six months prior to entering the coadministration study. Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date, concluded the statement.